GO
Loading...

Novartis AG

More

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • Switzerland takes on its top drugmakers in price row Tuesday, 16 Sep 2014 | 5:46 AM ET

    *Roche, Novartis say low prices hurt R&D. ZURICH, Sept 16- Switzerland, home to the world's two biggest drugmakers, might be expected to give them an easy ride. But Roche and Novartis are finding no immunity in their home market from a European-wide price squeeze.

  • *Roche, Novartis say Lucentis is most appropriate drug. Avastin is not licensed for wAMD but it works in a similar way to authorized treatments for the condition- Lucentis, which is marketed by Novartis and Roche, and Eylea, from Bayer and Regeneron Pharmaceuticals.

  • Weaker healthcare stocks weigh on European equities Tuesday, 2 Sep 2014 | 12:40 PM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- A fall in major healthcare stocks, after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer, pegged back European stock markets on Tuesday. "We wouldn't chase stocks at these levels," said HED Capital head Richard Edwards.

  • European equities dip as healthcare stocks weaken Tuesday, 2 Sep 2014 | 10:16 AM ET

    *Bid target AstraZeneca falls; CEO says "back to normal". LONDON, Sept 2- European shares slipped on Tuesday as major healthcare stocks fell after drugmaker AstraZeneca tried to play down speculation about a new bid from Pfizer. A 1.8 percent fall at AstraZeneca took the most points off the index.

  • BARCELONA, Sept 2- Though speculation is rife of a new Pfizer bid, AstraZeneca's chief executive is not holed up with advisers in London or New York. Strict British takeover rules limit what Soriot and other players can say about Pfizer's abortive attempt to buy AstraZeneca and the possibility of a resumption of talks.

  • *Novartis's LCZ696 and PCSK9 drugs could treat millions. Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies.

  • *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares edged higher to close near a recent one-month peak on Monday, with merger and acquisition speculation about British broadcaster ITV helping media stocks and Novartis leading drugmakers.

  • European shares tick higher, drugmakers advance Monday, 1 Sep 2014 | 11:17 AM ET

    *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares traded near a recent one-month peak on Monday, with merger and acquisition speculation about British broadcaster ITV helping media stocks and Novartis leading drugmakers. Novartis, up 4.7 percent, was the top gainer on the FTSEurofirst 300 index.

  • *Novartis boosts drugmakers on new drug prospects. LONDON, Sept 1- European shares edged higher to trade near a recent one-month peak on Monday, with mergers and acquisitions speculation surrounding British broadcaster ITV helping media stocks and Novartis leading drugmakers.

  • *Novartis sees margins on LCZ696 better than for Diovan. BARCELONA, Sept 1- Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease.

  • *FTSEurofirst 300 up 0.1, Euro STOXX 50 flat. LONDON, Sept 1- European shares kicked off September on a flat note as investors weighed mergers and acquisitions speculation and expectations of new monetary largesse in Europe against tensions in Ukraine and weak economic data out of China.

  • Shares of United Therapeutics closed up $26.14 at $117.83 on the Nasdaq, boosting the company's market value by about $1.24 billion to $5.57 billion.

  • In afternoon trading, United Therapeutics' shares were up $24.56, or 26.8 percent, at $116.25, after earlier rising as much as 28.7 percent to a record $118.00.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Hospira filed a lawsuit in U.S. District Court in Maryland on Tuesday asking for a temporary restraining order against the FDA, saying the agency's decision to allow generic Precedex went against its own rules.

  • *Novartis move adds to Big Pharma retreat from antibiotics R&D. ZURICH, Aug 20- Novartis has signed a licensing deal to hand over its experimental tuberculosis drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.

  • NEW YORK/ WASHINGTON, Aug 9- All three U.S. facilities established to quickly make vaccines and therapeutics in the event of a major public health threat say they are standing by to support any U.S. government effort to scale up a treatment for Ebola.

  • NEW YORK,- A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.